MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Pulmonx Corporation Cost of Revenue 2011-2026 | LUNG
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Pulmonx Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.4 M | 21.8 M | 17.9 M | 13.8 M | 12.8 M | 11.5 M | 10.2 M | 7.72 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.4 M | 7.72 M | 14.9 M |
Quarterly Cost of Revenue Pulmonx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.45 M | 6.66 M | 6.2 M | - | 5.36 M | 5.48 M | 4.78 M | - | 4.64 M | 4.46 M | 3.95 M | - | 3.35 M | 3.53 M | 2.67 M | - | 3.52 M | 3.17 M | 2.63 M | - | 3.15 M | 2.66 M | 2.97 M | - | 2.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.66 M | 2.63 M | 4.07 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
232 M | $ 11.75 | -3.29 % | $ 1.76 B |  USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 8.98 | -1.32 % | $ 322 M | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
194 M | $ 6.32 | -2.02 % | $ 168 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 100.97 | 1.78 % | $ 1.28 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 62.4 | -1.33 % | $ 3.4 B |  Britain |
 |
LENSAR
LNSR
|
27.6 M | $ 5.56 | -8.4 % | $ 64 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 86.58 | -0.68 % | $ 111 B | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
InspireMD
NSPR
|
6.33 M | $ 1.79 | 3.47 % | $ 115 M |  Israel |
 |
Orthofix Medical
OFIX
|
256 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
Profound Medical Corp.
PROF
|
3.92 M | $ 5.15 | -4.63 % | $ 180 M | Canada |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Penumbra
PEN
|
461 M | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
14 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 225.5 | -0.7 % | $ 15.9 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.4 | -1.64 % | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
Quanterix Corporation
QTRX
|
73.9 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
72.7 M | $ 3.53 | -2.35 % | $ 53.7 K | USA |